LOADING
Cancer ratings in the VA system follow a distinctive two-stage pattern. During active disease and treatment, a 100 percent rating is assigned. After treatment ends and a six-month surveillance period passes, the rating is re-evaluated based on residuals of the disease and treatment. Understanding this framework applies across cancer types and helps veterans and families plan for both the acute treatment period and long-term compensation.
The general framework for cancer ratings is codified in the specific diagnostic codes for each cancer type within 38 CFR 4.112 through 4.118. Cancer in the respiratory system is under DC 6819, cancer in the genitourinary system under DC 7528, cancer in the digestive system under DC 7343, cancer in the hemic and lymphatic system under DC 7715 and related codes, skin cancer under DC 7833 and 7834, and so on. Each code assigns a 100 percent rating during active disease.
The active rating period includes the time of surgery, chemotherapy, radiation therapy, immunotherapy, hormonal therapy, or other active treatment. The 100 percent rating continues for at least six months after the last treatment. During this post-treatment observation period, the VA monitors for recurrence or persistent effects before re-evaluating.
The six-month re-examination is a mandatory component of the rating framework. After the six-month period, the VA schedules a C&P examination to assess the status of the disease, residuals, and any recurrence. The examination evaluates whether the cancer is in remission, partial response, stable disease, or has recurred.
Residual ratings are applied under the diagnostic codes for the affected body system, reflecting any functional impairment that persists after treatment. For breast cancer, residuals may include mastectomy-related scarring, lymphedema, and chronic pain, each potentially ratable under applicable codes. For colon cancer, residuals may include stoma-related issues or bowel dysfunction. Each cancer type has specific common residuals.
Chemotherapy and radiation residuals can include peripheral neuropathy, cardiomyopathy from certain chemotherapy agents, radiation damage to organs adjacent to the treated area, infertility, and cognitive effects sometimes called chemo brain. Each can be separately rated when present and medically documented.
Recurrence or metastasis restarts the 100 percent rating cycle. If cancer returns after the original treatment, the veteran returns to 100 percent during the active disease and treatment for the recurrence, plus another six-month post-treatment period before re-evaluation. This can produce periods of 100 percent rating alternating with residual-based ratings.
Many cancers are presumptive under various service connection frameworks. Agent Orange presumptive cancers include respiratory cancers, prostate cancer, various soft tissue sarcomas, multiple myeloma, non-Hodgkin lymphoma, and others. PACT Act burn pit presumptive cancers include many of the same cancers for post-9/11 veterans. Radiation-exposed atomic veterans have 21 presumptive cancers. Camp Lejeune presumptives include certain cancers linked to contaminated water. Military sexual trauma (MST) is recognized as increasing risk for certain cancers, though the specific framework differs.
Evidence for a cancer claim includes pathology reports with biopsy results and staging, oncology consultation and treatment notes, imaging studies, surgical reports, chemotherapy and radiation treatment records, current status documentation, and DD-214 and deployment records to establish qualifying service for presumptive claims.
Early cancer claims filing is strategically important. File as soon as the diagnosis is established, even before treatment begins. The effective date of compensation is the date of claim or date of entitlement, so early filing maximizes back pay. Intent to file under VA Form 21-0966 can establish an effective date for up to one year while you prepare the full claim.
During active treatment, the 100 percent rating provides financial support that can help with treatment-related expenses, travel, and the financial impact of reduced work capacity. Combined with other VA benefits like healthcare, travel reimbursement, and caregiver support programs, the benefit package during active treatment can be substantial.
Post-treatment planning should anticipate the re-examination. Document all residuals carefully. Continue routine oncology follow-up including imaging and laboratory monitoring. Keep a symptom log documenting fatigue, pain, neuropathy, and any ongoing treatment effects. Obtain current pulmonary function tests, cardiac evaluations, or other testing relevant to your specific cancer and its residuals.
Specially Adapted Housing and other adaptive benefits may be available for veterans with severe cancer residuals producing mobility or functional limitations. Review eligibility under 38 CFR 3.809 and related provisions.
Survivor benefits under DIC are available when a veteran dies of a service-connected cancer. Under 38 USC 1318, DIC also applies when a veteran had P&T status for 10 or more years regardless of cause of death. Families of veterans with cancer should be aware of these benefits.
The Claim Recon Rating Calculator helps families model how the active 100 percent cancer rating combines with other benefits, and how transition to residual ratings may affect long-term compensation. The Secondary Condition Finder maps cancer types to their common residuals and secondary conditions. The Personal Statement Builder helps you document treatment history, residuals, and functional impact.
Disclaimer: This article is for educational and informational purposes only. It does not constitute legal, medical, or VA claims advice. Cancer rating criteria and presumptive provisions are subject to change. Always verify current criteria at VA.gov or consult with an accredited VSO, attorney, or claims agent before making decisions about your benefits.
Written by Claim Recon Editorial